| Bioactivity | HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC50 of 5.7 nM[1][2][3]. | |||||||||
| Target | IC50: 5.7 nM (ATX) | |||||||||
| Invitro | HA-155 inhibits ATX by binding to the ATX active site[1].HA155 completely attenuates the thrombin-mediated increase in platelet-derived LPA in a dose-dependent manner[3]. | |||||||||
| Name | HA155 | |||||||||
| CAS | 1312201-00-5 | |||||||||
| Formula | C24H19BFNO5S | |||||||||
| Molar Mass | 463.29 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Albers HM, et al. Chemical Evolution of Autotaxin Inhibitors. Chem Rev. 2012 May 9;112(5):2593-603. [2]. Albers HM, et al. Structure-based design of novel boronic acid-based inhibitors of autotaxin. J Med Chem. 2011 Jul 14;54(13):4619-26. [3]. Fulkerson Z, et al. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem. 2011 Oct 7;286(40):34654-63. |